Tag: Cancer: Prostate

Findings show promise compared with usual care but warrant a larger trial, the authors say

Patient-reported outcomes appear to be similar to postoperative conventionally fractionated radiotherapy

Absence of progression correctly identified by subsequent MRI in nearly 95, 90, 70 percent of men with grade group 0, 1, 2, respectively

A more recent prostatectomy was associated with lower likelihood of pGG1 prostatectomy in two cohorts

UHF noninferior to conventionally fractionated radiotherapy for men with intermediate- to high-risk localized disease

PROSTOX predicts late genitourinary toxicity, yielding area under the curve of 0.76

Targeted screening to participants in ≥90th percentile of polygenic risk score results in detection of cancer warranting clinical management in 55.1 percent

Use of NeuroSAFE to guide nerve-sparing surgery results in improvement in erectile function at 12 months and urinary continence at three months

Physician-scored and patient-reported bowel toxicity higher with dose-escalated moderately hypofractionated radiotherapy

Authors say PSA level should be assessed for at least three months after radical prostatectomy for prostate cancer to accurately document persistent PSA